

*林美惠助理教授

所有發表期刊論文

1. CJ Chen, **MH Lin**, JC Shu, JJ Lu. **2014**. Reduced susceptibility to vancomycin in isogenic *Staphylococcus aureus* strains of sequence type 59: Tracking evolution and identifying mutations by whole-genome sequencing. *Journal of Antimicrobial Chemotherapy*. 69:349-354
2. YT Hsieh, **MH Lin***, HY Ho, CC Chen, LC Chen, JC Shu. **2013**. Glucose-6-phosphate dehydrogenase (G6PD)-deficient epithelial cells are less tolerant to infection by *Staphylococcus aureus*. *PLoS ONE* 8:e79566. (*Co-first author)
3. **MH Lin**, JF Fu and ST Liu. **2013**. A repeat 1 sequence causes competition of ColE1-type plasmids. *PLoS ONE* 8:e61668 [SCI, Impact Factor: 3.73]
4. **MH Lin** #, JC Shu, HY Huang and YC Chang. **2012**. Involvement of iron in biofilm formation by *Staphylococcus aureus*. *PLoS ONE* 7: e34388 (#correspondence)
5. CY Hsu *, **MH Lin** *, CC Chen, SC Chien, YH Cheng, IN Su, JC Shu. **2011**. Vancomycin promotes the bacterial autolysis, release of extracellular DNA, and biofilm formation in vancomycin-non-susceptible *Staphylococcus aureus*. *FEMS Immunology & Medical Microbiology*. 63:236-247 (*Co-first author)
6. **MH Lin**, FR Chang, MY Hua and ST Liu., **2011**. "Inhibitory effect of 1,2,3,4,6-penta-O-galloyl- β -D-glucopyranose on biofilm formation by *Staphylococcus aureus*", *Antimicrob. Agents Chemother.* 55:1021-7.
7. HY Chen, CC Chen, CS Fang, YT Hsieh, **MH Lin**, and JC Shu. **2011**. "Vancomycin activates σ^B in vancomycin-resistant *Staphylococcus aureus* resulting in the enhancement of cytotoxicity". *PLoS ONE*. 6:e24472.
8. **MH Lin** and ST Liu., **2008**. "Stabilization of pSW100 from *Pantoea stewartii* by F conjugation system", *J. Bacteriol.* 190:3681-3689.
9. **MH Lin**, WH Lan, TZ Liu. **2004**. Arecolin induce cell cycle dysregulation and apoptosis in gingival fibroblast. *J. Biomed. Lab. Sci.* 16:16-22
10. **MH Lin**, CH Tseng, CC Tseng, CH Huang, CK Chong, CP Tseng. **2001**. Real-time PCR for rapid genotyping of angiotensin-converting enzyme insertion/deletion polymorphism. *Clinical Biochemistry* . 34:661-666.

11. **MH Lin**, Tt Kuo. **2001**. Specificity of the histopathological triad for the diagnosis of toxoplasmic lymphadenitis: Polymerase chain reaction study. Pathology International. 51:619-623. [SCI, Impact Factor:1.521]
12. CP Tseng, CH Huang, CC Tseng, **MH Lin**, JT Hsieh, CH Tseng. **2001**. Induction of Disabled-2 gene during megakaryocyte differentiation of K562 cells. Biochem Biophys Res Commun. 285:129-135. [SCI, Impact Factor: 2.548]
13. CF Sun, CH Lee, SW Cheng, **MH Lin**, TL Wu, KC Tsao, DTY Chiu, JD Liou, DC Chu. **2001** Real-time quantitative PCR analysis for α -thalassemia-1 of Southeast Asian type deletion in Taiwan. Clinical Genetics 60:305-309. [SCI, Impact Factor: 3.304]
14. **MH Lin**, TC Chen, Tt Kuo, CC Tseng and CP Tseng. **2000**. Real-time polymerase chain reaction for quantitative detection of Toxoplasma gondii. Journal of Clinical Microbiol.: 38:4121-4125. [SCI, Impact Factor:4.162]
15. JJ Yeh, **MH Lin**, SW Chao, JS Wei. **1999**. Quantitative Determination of Digoxin-like immunoreactive factor by an alkaline phosphatase-based chemiluminescent immunoassay. Journal of Biomedical & Laboratory Sciences. 11: 88-92.
16. SL Doong, **MH Lin**, MM Tsai, TR Li, SE Chuang and AL Cheng. **1998**. Transactivation of the human MDR1 gene by Hepatitis B virus X gene product. Journal of Hepatology. 29 : 872-878. [SCI, Impact Factor:7.818]
17. **MH Lin**, CP Liao, JS Lee, YW Chin, CC Hsu, JS Wei. **1998**. Detection of endogenous digitalis-like immunoreactive factors in human blood. Proceedings of the National Science Council, ROC Part B: Life Sciences; 22:129-135.